GeoVax Labs (GOVX) Emerging Growth Conference 78 summary

Strategic focus and guiding principles

• Operates as a Phase 2 clinical-stage biotech with a focus on innovation, differentiation, acceleration, and collaboration.

• Holds over 120 granted or pending patents across 24 families, targeting underserved patient populations.

• Maintains global rights for all assets and actively seeks partnerships for broad distribution.

• Prioritizes three main programs: next-generation COVID-19 vaccine, mpox/smallpox vaccine, and Gedeptin solid tumor therapy.

Next-generation COVID-19 vaccine program

• Awarded a $400 million BARDA grant for a 10,000-patient trial comparing its vaccine to Moderna's, with study activation expected in October 2025.

• Vaccine shows 8–12 months durability and broad protection from Wuhan to Omicron strains, including strong T cell response.

• Interim trial results in CLL patients showed superior efficacy over Pfizer's vaccine, with plans for expedited registration if final results hold.

• Global rights and ongoing partnership discussions aim to address the needs of over 400 million immunocompromised adults worldwide.

Mpox/smallpox vaccine initiative

• WHO declared mpox a public health emergency; current global supply is insufficient and monopolized by a single supplier.

• GeoVax has completed GMP clinical material production and is finalizing packaging, aiming for lower-cost supply.

• Plans to initiate a rapid immuno-bridging trial in 2024, with potential for emergency use and first revenues from this product.

• Actively pursuing non-dilutive funding from international agencies and expects to update on funding progress.